Document

8/3/2019 www_sec_gov_Archives_edgar_data_1365216_000115752311005842_a
1/66
pdfcrowd comopen in browser PRO version Are you a developer? Try out the HTML to PDF API
EX 99.1 2 a5003 8211ex99_1.htm EXHIBIT 99.1Exhibit 99.1
http://pdfcrowd.com/redirect/?url=http%3a%2f%2fwww.sec.gov%2fArchives%2fedgar%2fdata%2f1365216%2f000115752311005842%2fa50038211ex99_1.htm&id=ma-111023224151-1a02bdd3http://pdfcrowd.com/customize/http://pdfcrowd.com/http://pdfcrowd.com/redirect/?url=http%3a%2f%2fwww.sec.gov%2fArchives%2fedgar%2fdata%2f1365216%2f000115752311005842%2fa50038211ex99_1.htm&id=ma-111023224151-1a02bdd3http://pdfcrowd.com/customize/http://pdfcrowd.com/html-to-pdf-api/?ref=pdf

2/66
Applying scienti fic and medical le adership in prostones to develop and commerciali ze therapeuti cs for an aging population James J. Egan Chief Operating Officer Asof October 21, 2011
http://pdfcrowd.com/http://pdfcrowd.com/redirect/?url=http%3a%2f%2fwww.sec.gov%2fArchives%2fedgar%2fdata%2f1365216%2f000115752311005842%2fa50038211ex99_1.htm&id=ma-111023224151-1a02bdd3http://pdfcrowd.com/customize/http://pdfcrowd.com/html-to-pdf-api/?ref=pdf

3/66

4/66
Forward Looking Stateme nts Forward looking stateme nts contained in this presentation are based on Sucampos assumptionsa nd eventse xpectati ons concerning future events. They are subject to significant business, economic and competit ive risksand uncertainti es that could cause actual resultst o differ materiall y from those reflecte d in the forward looking state ments. Sucamposforward looking
statement s could be affected by numerousp g y foreseeable and unforeseeable events and developments such asregula tory delays, the failure of clinic al trials, the inabili ty to fund drug development initiati ves, competiti ve productsand other factors identified in the Risk Factors section of Sucampos Annual Report on Form 10 Kand other periodic reports filed with the Securitie s and Exchange
Commission. While Sucampo may elect to update these state ments at some point in the future Sucampo specifical ly disclaims any obligation to do so, whether asa re sult of new information, future events or otherwise. In light of the significant uncertainti es inherent in the forward looking information in this presentation, you are cautioned not to place undue reliance on these forward looking statement s. 2

5/66

6/66
Sucampo Investment HighlightsProven technology: Leadership in prostones key ion channel activat orswith vali dated acti vators, clinica l utilit y Commercial products focused on large patie nt populations: AMITIZA approved in the U.S.; RESCULA was approved in the U.S. and wasa pproved in 45 countries; on market in Japan Clinical e xpansion: AMITIZA label expansion strategies underway in the
U.S., Europe and Asia; RESCULA label expansion strategie s underway in the U.S. and Europe Robust pipeline: Revenue stream fuel ing advances in proprietary prostone based portfolio 3

7/66

8/66
ProstonesClass of compounds derived from endogenousfunct ional fatty acids with wound healing and restorative properties* Selectivel y activate ion channels that modulate key pathwaysMeta bolize quickly into inactive form useful for locali zed effect in specific organsBroad and validated therapeuti c applicabil ity can be targeted to induce specific pharmacological effec ts** *Blikslager AT et al.
Comparison of the chloride cha nnel acti vator lubiprostone and the oral laxative Polyet hylene Glycol 3350 on Mucosal Barrier Repair in ischemic injured porcine intestine. World J Gastroenterol 2008 Oct 21;14(39):6012 7. **Cuppoletti J et al. SPI 0211 activate s T84 cell chloride t ransport and recombinant human ClC 2 chloride currents Am JPhysiol Cell Physiol 287:C1173 C1183, 2004 4

9/66
df d mi b PRO i Are you a developer? Try out the HTML to PDF API

10/66
df di b PRO i Are you a developer? Try out the HTML to PDF API
ProstonesAct as Selecti ve Potassium Channel (BK) and/or Selecti ve Chloride (ClC 2) Channel acti vators ClC 2 Channel stimulators (lubiprostone and cobiprostone) Restore endothelial and epithel ial barrier functions* Stimulate wound repair** Restore tight junction, restore membrane inte grity and normal trans membrane resistance Restore normal fluid circulation and modulate fluid transit across cell
membranes Tsukita et. Japa nese BioChemical Socie ty Meeting. Lubiprostone, a ClC 2 chloride channel activa tor, down regulates the DSS induced inflamma tion. **Blikslager AT Am JPhysiol Gastointest Liver Physiol 2007 Feb;292(2):G647 56. Epub 2006 Oct 19 5

11/66
df di b PRO i A d l ? T t th HTML t PDF API

12/66df di b PRO i A d l ? T t th HTML t PDF API
ProstonesBK Channel Stimulators (unoprostone isopropyl) Down regulate inflamm ation, hypoxia and edema* Block pro apoptotic and excito toxic effect s** Block the vaso constrictive and pro inflammatory effects of endothelin in the microvasculature Reduce normal fluid pressure in the eye*** Demonstrate neuroprotective effects in preclinica l ophthalmology models (light induced injury)****
Demonstrate dose dependent neuroprotecti ve effects in clinica l studies glaucoma (head to head vs in longitudinal studies vs.latanoprost***** in Japan) and retinitis pigmentosa****** (phase 2b in Japan) * Yu DYet al. Invest Ophthalmol Vis Sci 1994: 35:4087 4099. Kern TS. Exp Diabete s Res. 2007: 2007: 95013. Hardy P et al. Prostaglandins Leukot Essent Fatty Acids. 2005: 72(5): 301 325 **Sugiyama T
et al. Arch Ophthalmol. 2009;127:454 459 *** Inoue Ket a l. Cli nical Ophthalmology 2011:5 1003 1005 ****Hayami K et al. Ophthalmic Res. 2001 Jul Aug;33(4):203 9 and Melamed S. DrugsExp Cli n Res 2002;28(2 3):63 73. *****Ishida T al. Topica l Monotherapy for Normal Tension Glaucoma Comparison of Long term Monotherapies in Maintaining Visual Fiel d Ophthalmology 47:1107 1112,2005.
*

Date post:	07-Apr-2018
Category:	Documents
Upload:	anonymous-lc9dgg
View:	215 times
Download:	0 times

Document

Documents